JUN 20, 2019 10:16 AM PDT

Sickle cell drug promising in clinical trial

WRITTEN BY: Nouran Amin

UConn School of Medicine researchers report that an investigational drug used for treating for the sickle cell disease has shown promising results in early clinical trials. Specifically, the experimental drug IMR-687 was shown to reduce two impact factors— sickling of red blood cells and blood vessel blockages. These factors result in debilitating pain, organ damage and early patient mortality.

Learn more on sickle cell disease, also known as sickle cell anemia:

“After 13 weeks of testing in its current clinical trial, the orally administered, once-a-day phosphodiesterase 9 (PDE9) inhibitor in adult patients with sickle cell disease is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease,” says Dr. Biree Andemariam, lead investigator for the clinical trial, associate professor of medicine at UConn School of Medicine and director of the New England Sickle Cell Institute at UConn Health. "These initial Phase 2a data demonstrate the potential of IMR-687 to significantly impact key biomarkers associated with the pathology of this serious disease.”

The drug has been granted U.S. Orphan Drug Designation, U.S. Rare Pediatric Designation, and Fast Track Designation by the Food and Drug Administration (FDA).

University of Connecticut: In sickle cell disease, a patient's red blood cells are abnormally sickle – or crescent – shaped, which can lead to painful blood vessel blockages. (Getty Images)

"We are encouraged by this interim Phase 2a analysis that reinforces our belief in the potential of IMR-687 as a single oral, once-a-day therapeutic," said Rahul D. Ballal, chief executive officer of Imara. "IMR-687 uniquely targets both red cell and white cell aspects of the disease, and we are working to expeditiously advance this novel therapy through clinical development, with a goal of delivering it to patients with SCD who are in need of innovative treatment options."

"The interim Phase 2a data reflect trends that could be indicative of meaningful clinical translation of these important measures in sickle cell disease," Andemariam adds.

Source: University of Connecticut

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
SEP 20, 2021
Genetics & Genomics
Clinical Trial of CRISPR-Based HIV Treatment Set to Begin
SEP 20, 2021
Clinical Trial of CRISPR-Based HIV Treatment Set to Begin
Human immunodeficiency virus (HIV) is a retrovirus, which is a type of virus that can write its genetic material into th ...
SEP 27, 2021
Microbiology
Rift Valley Fever's Infectious Secret is Revealed
SEP 27, 2021
Rift Valley Fever's Infectious Secret is Revealed
Rift Valley fever virus is carried by mosquitoes, and when it's passed to livestock including cattle, goats, and sheep, ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
OCT 19, 2021
Microbiology
An Antibiotic May be Able to Reduce Inflammatory Pain
OCT 19, 2021
An Antibiotic May be Able to Reduce Inflammatory Pain
The gastrointestinal tract is full of microbes, all with their own genomes and characteristics. Some of those microbes a ...
NOV 05, 2021
Cannabis Sciences
Advances in Medical Cannabis for Treating Autism Spectrum Disorder
NOV 05, 2021
Advances in Medical Cannabis for Treating Autism Spectrum Disorder
Encouraging clinical evidence has recently sparked an emerging interest in the use of CBD-enriched medical cannabis as a ...
NOV 10, 2021
Drug Discovery & Development
Inflammation during pregnancy can affect normal brain development
NOV 10, 2021
Inflammation during pregnancy can affect normal brain development
During pregnancy the growing embryo and fetus undergo remarkable and quick developmental. Around 5 weeks after ...
Loading Comments...